Core Viewpoint - FormFactor (FORM) shows a significant improvement in earnings outlook, making it an attractive investment option as analysts continue to raise earnings estimates for the company [1][2]. Earnings Estimates - Analysts' optimism regarding FormFactor's earnings prospects is leading to higher estimates, which are expected to positively influence the stock price [2]. - The Zacks Rank system indicates that stocks with strong earnings estimate revisions tend to outperform, with Zacks 1 Ranked stocks averaging a +25% annual return since 2008 [3]. Current Quarter Estimates - For the current quarter, FormFactor is projected to earn $0.33 per share, reflecting a +43.5% increase from the same quarter last year [6]. - In the past 30 days, two earnings estimates for FormFactor have been revised upward, with no negative revisions, resulting in a 20% increase in the Zacks Consensus Estimate [6]. Current Year Estimates - For the full year, FormFactor's expected earnings are $1.58 per share, representing a +21.5% year-over-year increase [7]. - Over the last month, four estimates have been raised for FormFactor, with no negative revisions, contributing to a positive consensus outlook [7]. Zacks Rank - The favorable estimate revisions have earned FormFactor a Zacks Rank 1 (Strong Buy), indicating strong potential for investment based on earnings estimate trends [8]. - Research shows that stocks with Zacks Rank 1 and 2 significantly outperform the S&P 500 [8]. Stock Performance - FormFactor shares have increased by 31.5% over the past four weeks, indicating strong investor confidence in the company's earnings growth prospects [9].

Core Viewpoint - Plexus (PLXS) is positioned as a strong investment opportunity due to significant upward revisions in earnings estimates, indicating a positive earnings outlook that may continue to drive stock performance [1][11]. Earnings Estimate Revisions - Analysts have shown growing optimism regarding Plexus's earnings prospects, reflected in the upward trend of estimate revisions, which historically correlates with stock price movements [2]. - The current-quarter earnings estimate for Plexus is projected at $1.85 per share, representing an 11.5% year-over-year increase, with a 13.54% rise in consensus estimates over the last 30 days [7]. - For the full year, the earnings estimate stands at $7.61 per share, reflecting a 2.4% increase from the previous year, with a 5.27% boost in consensus estimates during the same timeframe [8][9]. Zacks Rank and Performance - Plexus currently holds a Zacks Rank 1 (Strong Buy), supported by strong agreement among analysts on upward earnings revisions, which historically leads to significant outperformance [3][10]. - Stocks rated Zacks Rank 1 have generated an average annual return of +25% since 2008, indicating a robust track record of success [3]. Stock Performance - Plexus has experienced a notable 30.8% gain over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects, suggesting it may be a timely addition to investment portfolios [11].

Core Insights - Auna S.A. has a strong history of beating earnings estimates, with an average surprise of 93.59% over the last two quarters, indicating potential for continued performance in upcoming reports [1][2] Earnings Performance - For the last reported quarter, Auna S.A. achieved earnings of $0.20 per share, exceeding the Zacks Consensus Estimate of $0.15 per share by 33.33% [2] - In the previous quarter, the company reported earnings of $0.33 per share against an expected $0.13 per share, resulting in a surprise of 153.85% [2] Earnings Estimates - Recent estimates for Auna S.A. have been trending upward, with a positive Earnings ESP of +44.00%, suggesting increased analyst optimism regarding the company's near-term earnings potential [5][8] - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) indicates a strong likelihood of another earnings beat [5][8] Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have historically produced positive surprises nearly 70% of the time, indicating a high probability of exceeding consensus estimates [6] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions and potentially more accurate predictions [7]

Core Viewpoint - Middlefield Banc Corp. (MBCN) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - Middlefield Banc has a solid track record of surpassing earnings estimates, with an average surprise of 17.45% over the last two quarters [2]. - In the most recent quarter, the company reported earnings of $0.65 per share against an expectation of $0.64, resulting in a surprise of 1.56% [2]. - For the previous quarter, the consensus estimate was $0.57 per share, while the actual earnings were $0.76 per share, leading to a surprise of 33.33% [2]. Earnings Estimates and Predictions - Estimates for Middlefield Banc have been trending upward, influenced by its history of earnings surprises [5]. - The company currently has a positive Zacks Earnings ESP of +1.54%, indicating that analysts are optimistic about its earnings prospects [8]. - The combination of a positive Earnings ESP and a Zacks Rank of 3 (Hold) suggests a strong possibility of another earnings beat [8]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 or better have a nearly 70% chance of producing a positive surprise [6]. - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, reflecting the latest analyst revisions [7]. Importance of Earnings ESP - It is crucial for investors to check a company's Earnings ESP prior to its quarterly release to enhance the likelihood of successful investment decisions [10].

Core Insights - The fourth-quarter earnings season is ongoing, with major pharmaceutical companies set to announce their results, including AstraZeneca, Incyte, Gilead Sciences, Vertex Pharmaceuticals, and Moderna [1] Industry Overview - Several large pharmaceutical companies such as Johnson & Johnson, Lilly, AbbVie, Biogen, Merck, and Amgen reported better-than-expected fourth-quarter results, surpassing estimates for both earnings and revenues. In contrast, Novartis and Sanofi had mixed results, with earnings exceeding estimates but revenues falling short [2] - As of February 4, 40% of companies in the Medical sector, representing 73.9% of the sector's market capitalization, reported quarterly earnings. Among these, 87.5% exceeded earnings estimates, and 75% surpassed revenue estimates. Year-over-year, earnings increased by 3.3%, while revenues rose by 9.5%. Overall, fourth-quarter earnings for the Medical sector are expected to decline by 1.5%, while sales are projected to increase by 9.1% compared to the previous year [3] Company-Specific Insights AstraZeneca - AstraZeneca's performance has been mixed, with earnings beating estimates in two of the last four quarters, meeting once, and missing once, resulting in an average surprise of 3.81%. The consensus estimate for fourth-quarter sales is $15.78 billion, with earnings expected at $2.18 per share [5] - Key medicines, particularly cancer drugs and diabetes medicine, are expected to drive fourth-quarter sales, supported by strong demand trends [7] - AstraZeneca is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [8] Incyte - Incyte has a mixed history of earnings surprises, beating estimates in three of the last four quarters, with an average surprise of 14.35%. The consensus estimate for fourth-quarter sales is $1.35 billion, with earnings expected at $1.94 per share [9] - Strong sales of Jakafi and expected growth in Opzelura sales are likely to contribute to revenue growth in the fourth quarter [11][12] - Incyte is also set to report its fourth-quarter and full-year 2025 earnings on February 10 [12] Gilead Sciences - Gilead Sciences has a mixed earnings surprise history, beating estimates in three of the last four quarters, with an average surprise of 7.80%. The consensus estimate for fourth-quarter sales is $7.57 billion, with earnings expected at $1.83 per share [13] - Increased sales from Biktarvy and Descovy, along with growth in the Liver Disease portfolio, are anticipated to drive top-line growth [14] - Gilead is scheduled to report its fourth-quarter and full-year 2025 results on February 10 [15] Vertex Pharmaceuticals - Vertex has a mixed earnings surprise history, beating estimates in two of the last four quarters, with an average surprise of 2.01%. The consensus estimate for fourth-quarter sales is $3.17 billion, with earnings expected at $5.07 per share [16] - Revenue growth is likely to be driven by higher sales of its cystic fibrosis medicine, Trikafta, and contributions from newer drugs [18] - Vertex is set to report its fourth-quarter and full-year 2025 results on February 12 [19] Moderna - Moderna has a strong earnings surprise history, beating estimates in all of the last four quarters, with an average surprise of 31.45%. The consensus estimate for fourth-quarter sales is $661.4 million, with expected earnings showing a loss of $2.60 per share [20] - Revenue is expected to be primarily driven by sales of COVID-19 vaccines, although demand has declined recently [22] - Moderna is scheduled to report its fourth-quarter and full-year 2025 earnings on February 13 [23]

Core Viewpoint - Investors in the Utility - Electric Power sector should consider Avista (AVA) and OGE Energy (OGE) for potential value opportunities, with a closer examination needed to determine which stock offers better value [1] Group 1: Zacks Rank and Earnings Outlook - Avista has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while OGE Energy has a Zacks Rank of 3 (Hold) [3] - The Zacks Rank emphasizes stocks with positive revisions to earnings estimates, suggesting that AVA has an improving earnings outlook [3] Group 2: Valuation Metrics - AVA has a forward P/E ratio of 15.04, compared to OGE's forward P/E of 18.09, indicating that AVA may be undervalued relative to OGE [5] - The PEG ratio for AVA is 2.13, while OGE's PEG ratio is 2.59, suggesting AVA has a more favorable growth outlook relative to its valuation [5] - AVA's P/B ratio is 1.27, while OGE's P/B ratio is 1.85, further indicating that AVA is potentially undervalued [6] Group 3: Value Grades - AVA has earned a Value grade of B, while OGE has a Value grade of C, suggesting that AVA is the more attractive option for value investors [6]

Core Viewpoint - Investors are evaluating Jacobs Solutions (J) and Advanced Drainage Systems (WMS) to determine which stock offers better value for investment at the current time [1] Group 1: Zacks Rank and Earnings Outlook - Both Jacobs Solutions and Advanced Drainage Systems currently hold a Zacks Rank of 2 (Buy), indicating a positive earnings outlook due to favorable analyst estimate revisions [3] - The Zacks Rank is a reliable indicator for value investors as it emphasizes companies with improving earnings forecasts [2] Group 2: Valuation Metrics - Jacobs Solutions has a forward P/E ratio of 20.88, while Advanced Drainage Systems has a higher forward P/E of 29.09 [5] - The PEG ratio for Jacobs Solutions is 1.54, compared to Advanced Drainage Systems' PEG ratio of 2.26, indicating Jacobs Solutions may be undervalued relative to its expected earnings growth [5] - Jacobs Solutions has a P/B ratio of 5.07, while Advanced Drainage Systems has a P/B ratio of 7, further suggesting that Jacobs Solutions is a more attractive value option [6] Group 3: Value Grades - Based on the valuation metrics, Jacobs Solutions has earned a Value grade of B, whereas Advanced Drainage Systems has received a Value grade of D, indicating a stronger value proposition for Jacobs Solutions [6]

Core Viewpoint - Concentrix Corporation (CNXC) is currently viewed as a better investment opportunity compared to Bowman Consulting (BWMN) based on various valuation metrics and earnings outlook [1][3][7] Valuation Metrics - CNXC has a forward P/E ratio of 3.40, significantly lower than BWMN's forward P/E of 22.17, indicating that CNXC may be undervalued [5] - The PEG ratio for CNXC is 0.39, while BWMN's PEG ratio stands at 1.15, suggesting that CNXC offers better value relative to its expected earnings growth [5] - CNXC's P/B ratio is 0.91, compared to BWMN's P/B of 2.33, further supporting the notion that CNXC is undervalued [6] Earnings Outlook - CNXC has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while BWMN has a Zacks Rank of 4 (Sell), reflecting a less favorable outlook [3][7] - The improving earnings outlook for CNXC enhances its attractiveness as a value investment [7] Value Grades - CNXC holds a Value grade of A, while BWMN has a Value grade of C, reinforcing the assessment that CNXC is the superior value option at this time [6]

Core Viewpoint - The article compares Fox Corporation (FOX) and Fox (FOXA) to determine which stock is more attractive to value investors [1] Group 1: Zacks Rank and Earnings Outlook - Fox Corporation has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while Fox has a Zacks Rank of 3 (Hold) [3] - The improving earnings outlook for FOX suggests it is a more favorable option for investors [7] Group 2: Valuation Metrics - FOX has a forward P/E ratio of 12.51, compared to FOXA's forward P/E of 14.18 [5] - FOX's PEG ratio is 7.92, while FOXA's PEG ratio is 8.52, indicating FOX may be undervalued relative to its expected EPS growth [5] - FOX has a P/B ratio of 2.35, whereas FOXA has a P/B of 2.61, further supporting FOX's valuation attractiveness [6] - These metrics contribute to FOX's Value grade of B and FOXA's Value grade of C [6]

Core Insights - Rollins, Inc. (ROL) is scheduled to report its fourth-quarter 2025 results on February 11, with a strong earnings surprise history, surpassing the Zacks Consensus Estimate in two of the last four quarters and matching twice, averaging a 3.2% earnings surprise [1] Revenue Expectations - The Zacks Consensus Estimate for revenues in the upcoming quarter is $922.1 million, reflecting a year-over-year increase of 10.8% [2] - Residential revenues are estimated at $407 million, indicating a 10.3% increase from the previous year, while commercial revenues are expected to rise 11.4% year over year to $312.4 million [3] - Termite and ancillary revenues are projected at $195.5 million, suggesting a 13.4% growth year over year, with franchise revenues estimated at $4.3 million, showing a marginal rise [3] - U.S. revenues are pegged at $858.3 million, indicating an 11.3% increase from the year-ago quarter, while revenues from other countries are anticipated to grow 9.6% year over year to $66.9 million [5] Growth Drivers - The anticipated revenue growth is attributed to Orkin's expansion, which has the highest customer retention rate among the company's service lines, and the utilization of advanced digital tools such as BOSS, VRM, Orkin 2.0, BizSuite, and InSite [4] - Recent acquisitions of Saela Holdings and FPC Holdings are expected to enhance geographical exposure to favorable regions, while increased media engagement through social media platforms like TikTok and Facebook is likely to boost brand popularity [6] Earnings Outlook - The consensus estimate for earnings is set at 27 cents per share, indicating a year-over-year growth of 17.4% [6] - The bottom line is expected to benefit from the company's CPI-plus focused pricing strategies, which aim to keep prices above the general Consumer Price Index (CPI) rate to mitigate inflation effects [7] Earnings Prediction Model - The current model does not predict a definitive earnings beat for ROL, as it has an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold) [8]